Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 7/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312398 | 0.92 | CASP1 (0.60) | CASP1CTSKTACR1IDO1ALDH1A1 | |
| SCHEMBL8765627 | 0.92 | CASP1 (0.60) | CASP1CTSKTACR1IDO1ALDH1A1 | |
| SCHEMBL15254319 | 0.87 | CASP1 (0.50) | CASP1CTSKTACR1IDO1ALDH1A1 | |
| SCHEMBL5408318 | 0.87 | CASP1 (0.50) | CASP1CTSKTACR1IDO1ALDH1A1 | |
| SCHEMBL25491977 | 0.86 | MMP9 (0.52) | CASP1MMP9CTSKTACR1ALDH1A1 | |
| SCHEMBL9681600 | 0.85 | MMP9 (0.48) | CASP1MMP9TACR1ALDH1A1MAPK1 | |
| SCHEMBL14177313 | 0.84 | ALDH1A1 (0.53) | CASP1MMP9CTSKTACR1ALDH1A1 | |
| SCHEMBL28709501 | 0.84 | ALDH1A1 (0.53) | CASP1MMP9TACR1ALDH1A1MAPK1 | |
| SCHEMBL7583002 | 0.83 | CASP1 (0.60) | CASP1CTSKTACR1IDO1ALDH1A1 | |
| SCHEMBL2912589 | 0.83 | CASP1 (0.60) | CASP1CTSKTACR1IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169803-B2 | N-substituted prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050203089-A1 | N-substituted prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203089-A1 | N-substituted prodrugs of fluorooxindoles | KCNA5, KCNQ5, KCNQ2 | CASP1 1558/4885MMP9 2979/4885CTSK 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.